Drug Trial Radar · NCT04709328
To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
Last checked: Nov 19, 2026Latest source record: Mar 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
690
Planned (sponsor's estimate)
Start
Mar 28, 2021
Primary completion
Jan 1, 2022
Study completion Mar 1, 2022
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III clinical trial. It will be conducted at selected investigational sites globally. The study is comprised of 2 parts.
Conditions
- COVID-19
- SARS-CoV-2
Interventions
SCTA01Drug
Diluted by 0.9% normal saline,IV
PlaceboOther
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who experience COVID-19 related hospitalization (defined as at least 24 hours of acute care) or death (all cause) up to Day 29.Time frame: Day 29
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.